Therese Choquette

Chief Technical Officer Tigen Pharma SA

Scientist with PhD in Rheumatology, MS in Biomedicine, and background as a licensed practical nurse working with T cell-based cell therapies since 2014. Passionate about providing high quality cell and gene therapy to patients, and translational analyses combining CMC and clinical data (patient-to-product-to-patient for autologous products) to understand manufacturability, clinical efficacy, and adverse events. Experience in all stages of clinical studies from early development up to commercial phase, biotech and pharma, analytical development and QC labs. Participated in successful IND and BLA submissions, working closely with Regulatory CMC authoring sections and responding to questions from HA. Enjoying scientific writing and presentations, speaking at conferences on a regular basis. Long term experience in managing teams and projects and working in matrix environments, appreciates a collaborative environment. Skilled in immunology, immuno assays, assay development, qualifications/validations, GxP, analytical CMC, stability and comparability studies, quality control, ICH/FDA/EMA guidelines, US and EU Pharmacopeia.

Seminars

Thursday 19th November 2026
Accelerating TIL Manufacturing Through Automated QC Release Testing & Next-Generation Potency Assays
9:00 am
  • Sharing strategies to accelerate product release through automated quality control workflows, rapid sterility testing, and conditional release approaches to reduce manufacturing bottlenecks
  • Exploring how automation can improve consistency, scalability, and efficiency across TIL manufacturing while maintaining product quality and regulatory compliance
  • Discussing current challenges in developing meaningful potency assays for TIL products and evaluating emerging approaches to better characterize product function and predict clinical performance
Therese Choc - speaker for 8th TIL Therapies Summit